Curacyte's new approach to shock, Hemoximer, enters Phase III
16 June 2009
John Davis
Please Login to read the full article.
16 June 2009
John Davis
john.davis@informa.com
Curacyte Health Sciences's nitric oxide scavenger, Hemoximer (pyridoxalated haemoglobin polyoxyethylene, PHP), has entered a Phase III clinical trial in patients with distributive shock.
It is the company's only investigational product, and one of the few new products being evaluated for...
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA: J&J Doribax pneumonia study halted on higher deaths
- Nanobiotix begins Phase I trial of cancer nanoparticle but is it a drug or device?
- Jury still out on benefits of glucose lowering treatments, says German HTA body
- Zerit, Tygacil and Brinavess in latest CHMP restrictions
ANALYSIS
Other Informa Analysis
COMMENT
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
